Report cover image

Urokinase Market By Type (Urokinase Powder, Urokinase Solution) , By End User (Hospital, Clinics) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Publisher Allied Market Research
Published Jul 01, 2024
Length 280 Pages
SKU # ALMR19230461

Description

Urokinase Market By Type (Urokinase Powder, Urokinase Solution) , By End User (Hospital, Clinics) : Global Opportunity Analysis and Industry Forecast, 2024-2033


Urokinase Market
The urokinase market was valued at $1.8 billion in 2023 and is projected to reach $3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.
Urokinase is a clot-busting drug which helps the body produce substances necessary to dissolve blood clots. Chemically, urokinase is a serine protease and is also known as urokinase-type plasminogen activator (uPA). The compound was initially isolated from human urine and is present in blood & extracellular matrix of several tissues. The drug is injected intravenously and is strictly administered under medical supervision. The drug is used to treat several conditions such as pulmonary embolism, acute myocardial infarction, and deep vein thrombosis.
Increase in the prevalence of cardiovascular disorders owing to exponentially growing elderly population and significantly changing lifestyle is a major driver of the urokinase market. In addition, improvements in formulation and advancements in drug delivery systems are boosting the demand for urokinase as an efficient treatment solution. Expansion of the treatment horizon of urokinase is currently trending in the market, with the drug proving to be beneficial for the treatment of primary nephrotic syndrome and tuberculous pleurisy. The combined effect of the drug and antituberculous therapy is comparatively better for the treatment of tuberculous pleurisy, than the therapy alone. The integration of urokinase decreases residual pleural thickness, increases total pleural effusion, improves pulmonary function, and reduces pleural effusion absorption time. In primary nephrotic syndrome, urokinase prevents venous thromboembolism, coupled with minor bleeding events.
However, the risk of bleeding complications remains significant in various individuals, thereby restraining the growth of the urokinase market. Moreover, the predominant usage of alternatives, including latest anticoagulant therapies and tissue plasminogen activator (tPA), is presenting significant challenges for the market development. On the contrary, constant R&D efforts toward the refinement of formulations are presenting novel opportunities for market expansion as these improved formulations exhibit less side effects and enhance the patient compliance. For instance, a fresh precursor of urokinase, known as pro-urokinase, is under clinical trials currently. This inactive precursor ensures the involvement of its fibrin-specific physiologic properties during conversion into active urokinase that are known to enhance the efficacy of the drug.

Segment Review

The urokinase market is segmented into type, end user, and region. On the basis of type, the market is bifurcated into urokinase powder and urokinase solution. As per end user, it is divided into hospital and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the urokinase solution segment dominated the market in 2023.
As per end user, the hospital segment was the highest shareholder in 2023.
Region wise, the market is witnessing rapid expansion in Asia-Pacific.

Competition Analysis

The leading players operating in the global urokinase market include NDpharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc, Livzon Pharmaceutical Group Inc., Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, and Microbix Biosystems Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Key Market Segments

By Type

Urokinase Powder
Urokinase Solution

By End User

Hospital
Clinics

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
NDpharm
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
Techpool
Microbic Biosystems Inc
Livzon Pharmaceutical Group Inc.
Cadila Healthcare Limited
TAJ Pharmaceuticals Limited
Microbix Biosystems Inc

Table of Contents

280 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: UROKINASE MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Urokinase Powder
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Urokinase Solution
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: UROKINASE MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospital
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Clinics
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: UROKINASE MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Urokinase Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Urokinase Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Urokinase Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Urokinase Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Urokinase Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Urokinase Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Urokinase Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Urokinase Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest Of Europe Urokinase Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Urokinase Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Urokinase Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. Australia Urokinase Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. India Urokinase Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Urokinase Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Urokinase Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Urokinase Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Urokinase Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Urokinase Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Urokinase Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. NDpharm
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Wanhua Biochem
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Jiangxi Haoran Bio-Pharma
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Jiangsu Aidea Pharmaceutical
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Techpool
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Microbic Biosystems Inc
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Livzon Pharmaceutical Group Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Cadila Healthcare Limited
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. TAJ Pharmaceuticals Limited
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Microbix Biosystems Inc
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. UROKINASE MARKET FOR UROKINASE POWDER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. UROKINASE MARKET FOR UROKINASE SOLUTION, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. GLOBAL UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 5. UROKINASE MARKET FOR HOSPITAL, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. UROKINASE MARKET FOR CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. UROKINASE MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. NORTH AMERICA UROKINASE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 9. NORTH AMERICA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 10. NORTH AMERICA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 11. U.S. UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 12. U.S. UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 13. CANADA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 14. CANADA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 15. MEXICO UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 16. MEXICO UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 17. EUROPE UROKINASE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 18. EUROPE UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 19. EUROPE UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 20. GERMANY UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 21. GERMANY UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 22. FRANCE UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 23. FRANCE UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 24. UK UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 25. UK UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 26. ITALY UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 27. ITALY UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 28. SPAIN UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 29. SPAIN UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. REST OF EUROPE UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 31. REST OF EUROPE UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 32. ASIA-PACIFIC UROKINASE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 33. ASIA-PACIFIC UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 34. ASIA-PACIFIC UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 35. JAPAN UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 36. JAPAN UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 37. CHINA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 38. CHINA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 39. AUSTRALIA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 40. AUSTRALIA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 41. INDIA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 42. INDIA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. SOUTH KOREA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 44. SOUTH KOREA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 45. REST OF ASIA-PACIFIC UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 46. REST OF ASIA-PACIFIC UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 47. LAMEA UROKINASE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 48. LAMEA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 49. LAMEA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 50. BRAZIL UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 51. BRAZIL UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 52. SAUDI ARABIA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 53. SAUDI ARABIA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 54. SOUTH AFRICA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 55. SOUTH AFRICA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 56. REST OF LAMEA UROKINASE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 57. REST OF LAMEA UROKINASE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 58. NDPHARM: KEY EXECUTIVES
TABLE 59. NDPHARM: COMPANY SNAPSHOT
TABLE 60. NDPHARM: OPERATING SEGMENTS
TABLE 61. NDPHARM: PRODUCT PORTFOLIO
TABLE 62. NDPHARM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63. WANHUA BIOCHEM: KEY EXECUTIVES
TABLE 64. WANHUA BIOCHEM: COMPANY SNAPSHOT
TABLE 65. WANHUA BIOCHEM: OPERATING SEGMENTS
TABLE 66. WANHUA BIOCHEM: PRODUCT PORTFOLIO
TABLE 67. WANHUA BIOCHEM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68. JIANGXI HAORAN BIO-PHARMA: KEY EXECUTIVES
TABLE 69. JIANGXI HAORAN BIO-PHARMA: COMPANY SNAPSHOT
TABLE 70. JIANGXI HAORAN BIO-PHARMA: OPERATING SEGMENTS
TABLE 71. JIANGXI HAORAN BIO-PHARMA: PRODUCT PORTFOLIO
TABLE 72. JIANGXI HAORAN BIO-PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73. JIANGSU AIDEA PHARMACEUTICAL: KEY EXECUTIVES
TABLE 74. JIANGSU AIDEA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 75. JIANGSU AIDEA PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 76. JIANGSU AIDEA PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 77. JIANGSU AIDEA PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78. TECHPOOL: KEY EXECUTIVES
TABLE 79. TECHPOOL: COMPANY SNAPSHOT
TABLE 80. TECHPOOL: OPERATING SEGMENTS
TABLE 81. TECHPOOL: PRODUCT PORTFOLIO
TABLE 82. TECHPOOL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83. MICROBIC BIOSYSTEMS INC: KEY EXECUTIVES
TABLE 84. MICROBIC BIOSYSTEMS INC: COMPANY SNAPSHOT
TABLE 85. MICROBIC BIOSYSTEMS INC: OPERATING SEGMENTS
TABLE 86. MICROBIC BIOSYSTEMS INC: PRODUCT PORTFOLIO
TABLE 87. MICROBIC BIOSYSTEMS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88. LIVZON PHARMACEUTICAL GROUP INC.: KEY EXECUTIVES
TABLE 89. LIVZON PHARMACEUTICAL GROUP INC.: COMPANY SNAPSHOT
TABLE 90. LIVZON PHARMACEUTICAL GROUP INC.: OPERATING SEGMENTS
TABLE 91. LIVZON PHARMACEUTICAL GROUP INC.: PRODUCT PORTFOLIO
TABLE 92. LIVZON PHARMACEUTICAL GROUP INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93. CADILA HEALTHCARE LIMITED: KEY EXECUTIVES
TABLE 94. CADILA HEALTHCARE LIMITED: COMPANY SNAPSHOT
TABLE 95. CADILA HEALTHCARE LIMITED: OPERATING SEGMENTS
TABLE 96. CADILA HEALTHCARE LIMITED: PRODUCT PORTFOLIO
TABLE 97. CADILA HEALTHCARE LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98. TAJ PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 99. TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 100. TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
TABLE 101. TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 102. TAJ PHARMACEUTICALS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. MICROBIX BIOSYSTEMS INC: KEY EXECUTIVES
TABLE 104. MICROBIX BIOSYSTEMS INC: COMPANY SNAPSHOT
TABLE 105. MICROBIX BIOSYSTEMS INC: OPERATING SEGMENTS
TABLE 106. MICROBIX BIOSYSTEMS INC: PRODUCT PORTFOLIO
TABLE 107. MICROBIX BIOSYSTEMS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL UROKINASE MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF UROKINASE MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN UROKINASE MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALUROKINASE MARKET
FIGURE 10. GLOBAL UROKINASE MARKET SEGMENTATION, BY TYPE
FIGURE 11. UROKINASE MARKET FOR UROKINASE POWDER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. UROKINASE MARKET FOR UROKINASE SOLUTION, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. GLOBAL UROKINASE MARKET SEGMENTATION, BY END USER
FIGURE 14. UROKINASE MARKET FOR HOSPITAL, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. UROKINASE MARKET FOR CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 17. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 18. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 19. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 20. COMPETITIVE DASHBOARD
FIGURE 21. COMPETITIVE HEATMAP: UROKINASE MARKET
FIGURE 22. TOP PLAYER POSITIONING, 2023
FIGURE 23. NDPHARM: NET SALES, 2021-2023 ($BILLION)
FIGURE 24. NDPHARM: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 25. NDPHARM: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 26. WANHUA BIOCHEM: NET SALES, 2021-2023 ($BILLION)
FIGURE 27. WANHUA BIOCHEM: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 28. WANHUA BIOCHEM: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 29. JIANGXI HAORAN BIO-PHARMA: NET SALES, 2021-2023 ($BILLION)
FIGURE 30. JIANGXI HAORAN BIO-PHARMA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. JIANGXI HAORAN BIO-PHARMA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. JIANGSU AIDEA PHARMACEUTICAL: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. JIANGSU AIDEA PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. JIANGSU AIDEA PHARMACEUTICAL: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. TECHPOOL: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. TECHPOOL: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. TECHPOOL: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. MICROBIC BIOSYSTEMS INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. MICROBIC BIOSYSTEMS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. MICROBIC BIOSYSTEMS INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. LIVZON PHARMACEUTICAL GROUP INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. LIVZON PHARMACEUTICAL GROUP INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. LIVZON PHARMACEUTICAL GROUP INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. CADILA HEALTHCARE LIMITED: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. CADILA HEALTHCARE LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. CADILA HEALTHCARE LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. TAJ PHARMACEUTICALS LIMITED: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. MICROBIX BIOSYSTEMS INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. MICROBIX BIOSYSTEMS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. MICROBIX BIOSYSTEMS INC: REVENUE SHARE, BY REGION, 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us